DIRS.INFO The most relevant business & tech news

[1/2] A woman holds a Smith and Wesson handgun at the National Rifle Association's (NRA) annual meeting, in Indianapolis, Indiana, U.S., April 28, 2019. REUTERS/Bryan Woolston/File PhotoBOSTON, July 24 (Reuters) - The Mexican government on Monday urged a U.S. appeals court to revive a $10 billion lawsuit seeking to hold U.S. gun manufacturers responsible for facilitating the trafficking of weapons to drug cartels across the U.S.-Mexico border. Circuit Court of Appeals in Boston questioned whether a lower-court judge wrongly concluded that a U.S. law barred Mexico from suing Smith & Wesson Brands (SWBI.O), Sturm, Ruger & Co (RGR.N) and others. "What we want is an injunction to make these defendants start paying attention to their distribution systems," he said. "You have licensed manufacturers that sell to licensed distributors that sell to licensed retailers that sell to individuals who satisfy the requirements of federal law, but some of them happen to be straw purchasers," he said.

Persons: Smith, Bryan Woolston, Sturm, Steve Shadowen, Noel Francisco, William Kayatta, Kayatta, Nate Raymond, Bill Berkrot Organizations: Wesson, REUTERS, BOSTON, 1st U.S, Circuit, Wesson Brands, Ruger, Co, Beretta USA, Barrett Firearms Manufacturing, Colt's Manufacturing, Glock Inc, Smith & Wesson, Thomson Locations: Indianapolis , Indiana, U.S, Mexico, Boston, United States

Circuit Court of Appeals that two jurors had lied about whether they discussed the case on social media before being seated for his 2015 trial, an argument the U.S. Supreme Court did not address when it reinstated Tsarnaev's death sentence last year. Circuit Judge O. Rogeriee Thompson said it was "hard to understand" how the facts did not raise a potential claim of juror misconduct, and U.S. Circuit Judge William Kayatta questioned why the judge did not probe further. The Justice Department is defending Tsarnaev's death sentence despite President Joe Biden's opposition to capital punishment and a moratorium on federal executions issued by Attorney General Merrick Garland in July 2021. The case then returned to the 1st Circuit to address other grounds for appeal that neither court had yet to resolve.

[1/2] GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. Circuit Court of Appeals ruled that federal law preempts the plaintiffs' state-law claims that GSK failed to warn doctors and pregnant women that animal studies found a link between birth defects and taking Zofran. Louis Bograd, a lawyer for the plaintiffs at Motley Rice, did not respond to a request for comment. Without any newly acquired information, GSK could not legally change the label without the FDA's blessing, Kayatta wrote. For the plaintiffs: Louis Bograd of Motley RiceFor GSK: Lisa Blatt of Williams & ConnollyRead more:Zofran birth defect cases should be revived, say hundreds of plaintiffsGSK defeats 425 lawsuits alleging Zofran causes birth defects(NOTE: This story has been updated with a comment from GSK.)

Search resuls for: "William Kayatta"

3 mentions found